| P2093 | author name string | George I Papakostas | |
| | Richard C Shelton | |
| P2860 | cites work | An Inventory for Measuring Depression | Q26778503 |
| | A SELF-RATING DEPRESSION SCALE | Q28201088 |
| | Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice | Q29614979 |
| | Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report | Q29615999 |
| | 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release | Q32134744 |
| | Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management | Q34551484 |
| | Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation | Q34568196 |
| | Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. | Q35142087 |
| | Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients | Q35985928 |
| | The Mechanism of Action of Novel Antipsychotic Drugs | Q36515345 |
| | Clozapine: new research on efficacy and mechanism of action | Q38362817 |
| | Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile | Q40785107 |
| | The degree of inhibition of dopaminergic neurons in the ventral tegmental area induced by selective serotonin reuptake inhibitors is a function of the density-power-spectrum of the interspike interval | Q42441111 |
| | Selective serotonin reuptake inhibitors reduce the spontaneous activity of dopaminergic neurons in the ventral tegmental area | Q42461286 |
| | A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression | Q42686183 |
| | A novel augmentation strategy for treating resistant major depression | Q43514882 |
| | Long-term effects of olanzapine, risperidone, and quetiapine on ionotropic glutamate receptor types: implications for antipsychotic drug treatment | Q44493513 |
| | Aripiprazole as an adjunctive treatment for refractory major depression | Q45180533 |
| | A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression | Q46580881 |
| | Cortical 5-HT2A receptor signaling modulates anxiety-like behaviors in mice. | Q48437323 |
| | Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha 1-adrenergic and muscarinic receptors in vivo in rats | Q49068866 |
| | Radioreceptor binding profile of the atypical antipsychotic olanzapine | Q49130929 |
| | Anxious-depressive symptoms in schizophrenia: a new treatment target for pharmacotherapy? | Q51091024 |
| | Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. | Q55051636 |
| | The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression | Q57616579 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 253-259 | |
| P577 | publication date | 2008-01-08 | |
| P1433 | published in | Acta Psychiatrica Scandinavica | Q4033348 |
| P1476 | title | Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder | |
| P478 | volume | 117 | |